Study of Tumor Infiltrating Lymphocytes in Melanoma Patients
Author Information
Author(s): Niels Junker, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Primary Institution: Center for Cancer Immune Therapy (CCIT), Department of Oncology, University Hospital Herlev
Hypothesis
Can tumor infiltrating lymphocytes (TILs) be expanded to clinically relevant quantities for melanoma treatment?
Conclusion
The study successfully established a method for expanding TILs to clinically relevant numbers, showing sustained functionality against autologous tumors.
Supporting Evidence
- 50% of patients treated with TILs showed objective clinical responses.
- TILs were predominantly CD8+ T-cells, indicating their role in targeting tumors.
- Expansion of TILs to clinically relevant numbers was achieved within five weeks.
- TILs retained functionality and specific activity against autologous tumors.
- Different T-cell clonotypes were identified in expanded cultures.
Takeaway
Researchers found a way to grow immune cells from melanoma patients so they can be used to fight the cancer better.
Methodology
The study involved expanding TILs from tumor samples using a two-step culture process and assessing their characteristics and functionality.
Potential Biases
Potential bias due to the small sample size and lack of diversity in patient demographics.
Limitations
The study was limited to a small number of patients and specific tumor types.
Participant Demographics
Mean age of participants was 62 years with an equal gender distribution.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website